Placebo EC-18

DRUG2 trials

Sponsors

Enzychem Lifesciences Corporation

Conditions

Atopic DermatitisCOVID-19

Phase 2

To Evaluate Safety and Efficacy of EC-18 in COVID-19 Infection to Pneumonia

CompletedNCT04500132

Enzychem Lifesciences CorporationCOVID-19

Start: 2020-05-28End: 2021-02-15Updated: 2022-02-10

Determine the Dose-dependent Efficacy and Safety of EC-18 in Patients With Moderate to Severe Atopic Dermatitis

Not yet recruitingNCT06487000

Enzychem Lifesciences CorporationAtopic Dermatitis

Start: 2025-05-31End: 2026-12-31Target: 150Updated: 2024-11-08